STRATEC Biomedical AG
STRATEC Biomedical AG designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. T… Read more
STRATEC Biomedical AG - Asset Resilience Ratio
STRATEC Biomedical AG (SRBZF) has an Asset Resilience Ratio of 0.45% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how STRATEC Biomedical AG's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down STRATEC Biomedical AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.03 Million | 0.45% |
| Total Liquid Assets | $2.03 Million | 0.45% |
Asset Resilience Insights
- Limited Liquidity: STRATEC Biomedical AG maintains only 0.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
STRATEC Biomedical AG Industry Peers by Asset Resilience Ratio
Compare STRATEC Biomedical AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
LINDT & SPRUENGLI N - Dusseldorf Stock Exchang
DU:LSPN |
Other | 0.00% |
|
PRICELINE.COM
BE:PCE1 |
Other | 0.00% |
|
PRICELINE GROUP (PCE1.SG)
STU:PCE1 |
Other | 0.00% |
|
MURPHY USA
BE:1MU |
Other | 0.03% |
|
DIOS EXPLORATIONS
BE:BFM |
Other | 3.47% |
|
CHINA YUCHAI INTL (CYD.SG)
STU:CYD |
Other | 1.46% |
|
MEDIGENE N (MDG1.SG)
STU:MDG1 |
Other | 21.48% |
Annual Asset Resilience Ratio for STRATEC Biomedical AG (2014–2023)
The table below shows the annual Asset Resilience Ratio data for STRATEC Biomedical AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.15% | $683.00K | $466.58 Million | -0.09pp |
| 2022-12-31 | 0.24% | $958.00K | $397.50 Million | -0.18pp |
| 2021-12-31 | 0.42% | $1.54 Million | $368.52 Million | -0.06pp |
| 2020-12-31 | 0.48% | $1.59 Million | $331.90 Million | -4.26pp |
| 2017-12-31 | 4.74% | $12.50 Million | $263.78 Million | +2.53pp |
| 2016-12-31 | 2.21% | $5.70 Million | $257.97 Million | +1.28pp |
| 2015-12-31 | 0.93% | $1.48 Million | $158.94 Million | +0.71pp |
| 2014-12-31 | 0.22% | $307.00K | $137.75 Million | -- |